Company / R&D Expense
IOVANCE BIOTHERAPEUTICS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$300.3M
FY2025
5-year range
$259.0M / $333.2M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#61 of 210
Health Care
What the data says
At $300M, IOVANCE BIOTHERAPEUTICS, INC.'s r&d expense ranks #61 of 210 in the Health Care sector. Declined from $333M to $300M over the past 2 years.
Based on SEC 10-K filings.
$300M in FY2025 with a 5-year CAGR of +8.3%.
Declined from $333M to $300M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +8.3%
- 10-Year CAGR
- -
Sector benchmark
#61 of 210 in Health CareTop 29% of 210This company $300.3M Sector average $644.0M
▼
-53.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.3%, indicating consistent growth.
- In FY2025, r&d expense increased 8.7% year-over-year.
- Ranks #61 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $300.3M | +8.7% |
| FY2024 | $276.2M | -17.1% |
| FY2023 | $333.2M | +13.0% |
| FY2022 | $294.8M | +13.8% |
| FY2021 | $259.0M | +28.4% |
| FY2020 | $201.7M | +21.5% |
| FY2019 | $166.0M | +66.3% |
| FY2018 | $99.8M | +39.4% |
| FY2017 | $71.6M | +1760.6% |
| FY2016 | $3.8M | +78.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026